Compare AbCellera Biologics Inc (ABCL) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Prudential Financial Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Prudential Financial Inc trades at $112.62 (market cap $40.11B). The key difference: Prudential Financial Inc is far larger — about 17.1× AbCellera Biologics Inc's market cap, and Prudential Financial Inc pays a 4.85% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PRU | |
|---|---|---|
Market Cap | $2.35B | $40.11B |
Sector | Health | Financials |
52-Week High | $8.12 | $118.72 |
52-Week Low | $2.78 | $92.00 |
Enterprise Value | $1.99B | $67.16B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
PRU trades at $115.47, up 2.23% today, with a bullish technical signal and strong moving average support. The company reported a net income margin of 5.5% in 2025, with recent earnings beats in Q1 2026. Recent developments include expansion in India's life insurance market and new ETF launches by PGIM, highlighting growth initiatives.
Outlook remains positive due to solid profitability and strategic expansions, but risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, though the current price exceeds the $98.64 target, suggesting limited near-term upside amid steady operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
